Projecting readiness…
SMA-2048 · Private Client Portfolio Operations (synthetic)
A portfolio manager reviews the projection version, control outcomes, trades, and remaining warnings, then authorizes the release. A checksummed synthetic handoff package is generated. No order is created or routed.
Approved for handoff by an authorized portfolio manager. No order has been created, routed, or executed.
Approval reason
“All controls evaluated. No blockers remain. Accepting the residual model deviation from the approved substitution and the two documented wash-sale exposures.”
Warnings carried into the package
Synthetic demonstration package. No order was created, routed, or executed. All accounts, securities, prices, tax lots, policies, sources, and events are fictional. Not investment, legal, or tax advice.
Blocking
A hard stop or rebalance blocker that has not passed. Everything else can proceed in parallel.
Nothing is blocking
Every hard stop and rebalance blocker has passed against the current projection. Warnings and outstanding authorizations are listed below.
Non-blocking
Visible, deliberate, and preserved through release. A warning is not cleared by approving the handoff.
TLGR: 1 share difference ($58) is inside tolerance and is carried on the record rather than cleared.
Permitted resolution paths
Compare the custodian and internal lines side by side, choose an explicitly authorized correction path, and record the reason. The difference stays on the timeline after resolution.
Substitution approval for TRD-014 (replaces TRD-012): P. Raman (Portfolio Manager) on 2026-03-16 — "Kilder Energy Resources is the closest in-group substitute for the excluded Cedar Point Energy holding. Accepting the residual model deviation this creates in exchange for restriction compliance.".
Permitted resolution paths
Review the release package and record the approval with a reason. The approval binds to this exact projection.
Post-trade deviation of 4.61% is outside the mandate band of 1.50% but inside the illustrative strategy tolerance of 5.00%.
Permitted resolution paths
The residual gap is inside the strategy tolerance. It remains visible on the release record rather than being cleared.
2 potential wash-sale matches reviewed and accepted by M. Bell (Operations Analyst) on 2026-03-16: "Reviewed both matches: the 2026-02-25 Meridian Health purchase and the 2026-03-11 Novex Semiconductor purchase, each against a proposed loss sale of the same security. Treating both losses as at risk of disallowance and flagging them to tax reporting rather than changing the trades.".
Permitted resolution paths
Inspect the matching synthetic transaction, the source coverage boundary, and the timing, then record a reasoned review decision.